DEALS
Zhong Lun Advises Hisky Med on its Series B+ Financing
Zhong Lun Advises Hisky Med on its Series B+ Financing
Wuxi Hisky Medical Technologies Co., Ltd. (“Hisky Med") has recently completed its series B+ financing of over RMB 100 million from Kunpeng Yichuang New Energy Industry Equity Investment Fund Partnership (LP), Xinyu Beizeng Investment (LP), Wuxi Hi-Tech Venture Capital Equity Investment (LP), and Zaozhuang Zhonghui Equity Fund (LP). The newly raised funds will be used for market promotion and research and development of new products.
Acting as legal counsel for Hisky Med, Zhong Lun participated in the whole process of this financing. The team was led by partner Dean Ding, with support from associates Ling Pan and Yiqian Duan, among others.
Hisky Med is a leading researcher and developer of non-invasive detection of liver fibrosis equipment, boasting domestic and international market shares that have seldom been rivalled. Committed to upgrading the present technology to facilitate assessment of liver fibrosis in early diagnosis, Hisky Med has been conducting research and development of liver transient elasticity testing technology, together with Tsinghua University, for over ten years. The core brand of Hisky Med has become one of the global leading brands of non-invasive detection of liver, and products bearing the brand are mainly for early screening, diagnosis, and treatment assessment of chronic liver disease.
